• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, October 11, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Colon cancer: Dying cancer cells give neighboring tumor cells instructions on how to survive

Bioengineer by Bioengineer
November 17, 2022
in Biology
Reading Time: 3 mins read
0
Cancer Researcher Florian Greten
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

FRANKFURT. Colorectal carcinoma is the second most common cause of cancer death in Germany. Although cancer research in recent years has been able to significantly improve early diagnosis and therapy, the resistance of advanced colorectal tumours to common chemotherapies still constitutes a major problem and contributes substantially to the high mortality rate of patients with such tumours.

Cancer Researcher Florian Greten

Credit: Uwe Dettmar for Goethe University Frankfurt

FRANKFURT. Colorectal carcinoma is the second most common cause of cancer death in Germany. Although cancer research in recent years has been able to significantly improve early diagnosis and therapy, the resistance of advanced colorectal tumours to common chemotherapies still constitutes a major problem and contributes substantially to the high mortality rate of patients with such tumours.

When chemotherapeutic agents cause colon cancer cells to die, they release ATP (adenosine triphosphate) molecules, the cell’s energy currency, as a messenger substance. Researchers led by Professor Florian Greten at Georg-Speyer-Haus have now corroborated this in experiments. This ATP binds to certain receptors (P2X4 purinoreceptors) on the surface of surrounding tumour cells. This activates an important survival signalling pathway in these neighbouring cells, which protects them from cell death and makes the tumour resistant to therapy.

The cells killed off by the chemotherapy “warn” their neighbouring cells, as it were, and at the same time provide them with a survival strategy. However, if the communication between the dying tumour cells and their neighbours is interrupted – as the scientists were able to show in preclinical models – this raises the efficiency of the chemotherapy many times over, and tumours that were initially resistant respond very well to it.

Dr Mark Schmitt, first author of the study, explains: “Our research results demonstrate that – despite years of successful research – unknown mechanisms are still being discovered which show us how perfidiously tumour cells evade therapy. Our results now offer a new and promising starting point for substantially improving the response rate of advanced colorectal carcinomas to common chemotherapeutic agents by means of combination therapy.”

Professor Florian Greten, director of Georg-Speyer-Haus and spokesperson for the LOEWE Centre Frankfurt Cancer Institute explains: “We were surprised to see that tumour cells have developed communication mechanisms to the point that even the dying ones play an active role in ensuring their neighbours’ survival when under therapeutic ‘attack’. We hope very much that by interrupting the communication between the cells we can achieve this tremendous increase in the effect of standard therapy in patients as well.” The team now wants to work with colleagues at the Frankfurt Cancer Institute to test this new therapeutic concept in patients.



Journal

Nature

DOI

10.1038/s41586-022-05426-1

Method of Research

Experimental study

Subject of Research

Animals

Article Title

Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation.

Article Publication Date

16-Nov-2022

COI Statement

M. Schmitt, J.G. and F.R.G. have filed a patent regarding the use of P2X4 inhibitors in combination with cytotoxic compounds. F.J.d.S. is an employee of Genentech and owns Roche shares. F.R.G. is a consultant for Amazentis, which is a company not related to this study. All other authors declare no competing interests.

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Methylome Changes Drive Fiber Differentiation in Cotton

October 11, 2025
blank

New Framework Uncovers Differential Chromatin Interactions

October 11, 2025

Sex Differences in Pig Blood Gene Expression

October 11, 2025

RLCKs Phosphorylate RopGEFs to Regulate Arabidopsis Growth

October 10, 2025

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1212 shares
    Share 484 Tweet 303
  • New Study Reveals the Science Behind Exercise and Weight Loss

    102 shares
    Share 41 Tweet 26
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    98 shares
    Share 39 Tweet 25
  • Revolutionizing Optimization: Deep Learning for Complex Systems

    87 shares
    Share 35 Tweet 22

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Stretchable Biosensors Using Organic Transistors for Skin Integration

Advancing Gate Stack Engineering in 2D Transistors

Revolutionizing Health Systems: Insights from Ageing@Coimbra

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.